|Articles|June 15, 2003
- BioPharm International-06-01-2003
- Volume 16
- Issue 6
Small Biopharms Face Unique Challenges: Outsourcing in Early-Stage Drug Development
by Bruce Babbitt, PAREXEL International, JanHasker Jonkman, and Paul McKim By partnering with external drug development service providers, small biopharmaceutical start-ups can move their products out of the lab and into clinical development more efficiently.
Advertisement
Articles in this issue
over 22 years ago
SOX in the Boardroom: What the Sarbanes?Oxley Act Means to Youover 22 years ago
Inside Washington: Reshaping Biotech Drug Developmentover 22 years ago
BioTrends: M&A MalaiseNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
2
Pfizer Phase IIb Data Support Monthly GLP-1 Dosing for Obesity
3
SK bioscience Licensing Deal Targets Access Gaps in RSV Prevention
4
Industry Outlook 2026: How AI and Payer Pressure Impact Biopharma R&D (Part 1)
5
